Skip to main content
SpringerLink
Log in

Flow Cytometric Monitoring of Residual Disease in Acute Leukemia

  • Protocol
  • First Online:
Book cover Hematological Malignancies

Part of the book series: Methods in Molecular Biology ((MIMB,volume 999))

Abstract

Multiparameter flow cytometry offers the unique ability to simultaneously assess and correlate multiple cellular properties at the single cell level in a timely and efficient manner. Application of this technique to the detection of residual acute leukemia after therapy has been shown to be of singular importance to monitor response to therapy and provide prognostic information. Principles and methods that allow for the sensitive detection of acute leukemia following therapy are presented. The basic protocol outlines a simple and efficient method for the labeling of white cells with monoclonal antibodies directed against cell surface antigens. A second method describes a general method for the simultaneous assessment of surface and cytoplasmic antigens using a combination of fixation followed by membrane permeabilization. An illustrative panel of validated reagents currently in use for residual disease detection for acute lymphoblastic leukemia of B or T cell lineage as well as acute myeloid leukemia is provided. Principles of data analysis that allow for the reproducible detection of small populations of abnormal hematopoietic cells in peripheral blood and bone marrow are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wood BL (2004) Multicolor immunophenotyping: human immune system hematopoiesis. Methods Cell Biol 75:559–576

    Article  PubMed  Google Scholar 

  2. Craig FE, Foon KA (2008) Flow cytometry immunophentoyping for hematopoietic neoplasms. Blood 111:3941–3967

    Article  PubMed  CAS  Google Scholar 

  3. Vidriales MB, San-Miguel JF, Orfao A, Coustan-Smith E, Campana D (2003) Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol 16:599–612

    Article  PubMed  Google Scholar 

  4. Weir EG, Cowan K, LeBeau P, Borowitz MJ (1999) A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 13:558–567

    Article  PubMed  CAS  Google Scholar 

  5. Al-Mawali A, Gillis D, Hissaria P, Lewis I (2008) Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol 129:934–945

    Article  PubMed  Google Scholar 

  6. Wood B (2006) 9 and 10 color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 130:680–690

    PubMed  Google Scholar 

  7. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M et al (2011) New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 117:6267–6276

    Article  PubMed  CAS  Google Scholar 

  8. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL et al (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 111:5477–5485

    Article  PubMed  CAS  Google Scholar 

  9. Bruggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J et al German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107:1116–1123

    Google Scholar 

  10. Krampera M, Vitale A, Vincenzi C, Perbellini O, Guarini A, Annino L et al (2003) Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol 120:74–79

    Article  PubMed  Google Scholar 

  11. Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, Willman CL et al Children’s Oncology Group study (2003) Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children’s Oncology Group study. Leukemia 17:1566–1572

    Google Scholar 

  12. Bjorklund E, Mazur J, Soderhall S, Porwit-MacDonald A (2003) Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 17:138–148

    Article  PubMed  CAS  Google Scholar 

  13. Dworzak MN, Froschl G, Printz D, Mann G, Pötschger U, Mühlegger N et al Austrian Berlin-Frankfurt-Münster Study Group (2002) Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 99:1952–1958

    Google Scholar 

  14. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96:2691–2696

    PubMed  CAS  Google Scholar 

  15. Al-Mawali A, Gillis D, Lewis I (2009) The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom 76:91–101

    PubMed  Google Scholar 

  16. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T (2004) Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104:3078–3085

    Article  PubMed  CAS  Google Scholar 

  17. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC et al (2006) The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20:1783–1789

    Article  PubMed  CAS  Google Scholar 

  18. San Miguel JF, Vidriales MB, López-Berges C, Díaz-Mediavilla J, Gutiérrez N, Cañizo C et al (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746–1751

    Article  PubMed  CAS  Google Scholar 

  19. Wood BL, Levin GR (2006) Interactions between mouse IgG2 antibodies are common and mediated by plasma C1q. Cytometry B Clin Cytom 70:321–328

    PubMed  Google Scholar 

  20. Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O et al I-BFM-ALL-FCM-MRD-Study Group (2008) Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom. 74:150–5

    Google Scholar 

  21. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B (2005) Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the Children’s Oncology Group. Cytometry B Clin Cytom 68:18–24

    PubMed  Google Scholar 

  22. Baer MR, Stewart CC, Dodge RK, Leget G, Sulé N, Mrózek K et al (2001) High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 97:3574–3580

    Article  PubMed  CAS  Google Scholar 

  23. Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhlmann U et al (2005) Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring. Cytometry B Clin Cytom 63:1–9

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, University of Washington, Seattle, WA, USA

    Brent L. Wood

Authors
  1. Brent L. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, Dept. Pathology & Laboratory Medicine, Indiana University, West 11th Street 350, Indianapolis, 46202-5200, Indiana, USA

    Magdalena Czader

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, New York

About this protocol

Cite this protocol

Wood, B.L. (2013). Flow Cytometric Monitoring of Residual Disease in Acute Leukemia. In: Czader, M. (eds) Hematological Malignancies. Methods in Molecular Biology, vol 999. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-357-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-357-2_8

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-356-5

  • Online ISBN: 978-1-62703-357-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation